{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:38:27Z","timestamp":1789900707031,"version":"4.0.1"},"reference-count":61,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The myelodysplastic\/myeloproliferative neoplasms (MDS\/MPNs) lie at the interphase of phenotypically opposing bone marrow malignancies. They are characterized by concomitant features of bone marrow failure and myeloproliferation and are generally associated with a poor prognosis. Although much is unknown with respect to the clinical course and molecular biology of MDS\/MPNs, emerging research is beginning to uncover the key defining characteristics of this designation. In this review, we will discuss the features of MDS\/MPN diseases that unify there clinical and molecular course and those that define distinct disease entities. We will discuss advances in genetics and MDS\/MPN modeling, as well as translational discoveries that are anticipated to inform the diagnosis, prognostication, and treatment of MDS\/MPNs in the near future.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.349","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"349-354","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Surveying the landscape of MDS\/MPN research: overlap among the overlap syndromes?"],"prefix":"10.1182","volume":"2015","author":[{"given":"Eric","family":"Padron","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111705375262900_B1","first-page":"172","article-title":"The clinical management of chronic myelomonocytic leukemia","volume":"12","author":"Padron","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"2019111705375262900_B2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111705375262900_B3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2588.x","article-title":"Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia","volume":"76","author":"Invernizzi","year":"2006","journal-title":"Eur J Haematol"},{"issue":"8","key":"2019111705375262900_B4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.2698","article-title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia","volume":"45","author":"Sakaguchi","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"2019111705375262900_B5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2013","journal-title":"Leukemia"},{"issue":"15","key":"2019111705375262900_B6","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"issue":"7367","key":"2019111705375262900_B7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"19","key":"2019111705375262900_B8","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111705375262900_B9","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111705375262900_B10","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Broseus","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2019111705375262900_B11","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111705375262900_B12","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"key":"2019111705375262900_B13","doi-asserted-by":"crossref","first-page":"e3332014","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for the study of chronic myelomonocytic leukemia (CMML) validates modern prognostic scoring systems and demonstrates a critical need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Cancer J"},{"issue":"10","key":"2019111705375262900_B14","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111705375262900_B15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.beha.2013.09.005","article-title":"Refractory anemia with ring sideroblasts","volume":"26","author":"Malcovati","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"issue":"22","key":"2019111705375262900_B16","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111705375262900_B17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"issue":"17","key":"2019111705375262900_B18","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","article-title":"Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111705375262900_B19","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111705375262900_B20","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111705375262900_B21","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20131141","article-title":"Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo","volume":"210","author":"Abdel-Wahab","year":"2013","journal-title":"J Exp Med"},{"issue":"5","key":"2019111705375262900_B22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111705375262900_B23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2010-12-326058","article-title":"Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"7257","key":"2019111705375262900_B24","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"issue":"18","key":"2019111705375262900_B25","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2013-10-535104","article-title":"PI3K p110delta uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML","volume":"123","author":"Goodwin","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111705375262900_B26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1172\/JCI63193","article-title":"Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice","volume":"123","author":"Chang","year":"2013","journal-title":"J Clin Invest"},{"issue":"22","key":"2019111705375262900_B27","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","article-title":"The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111705375262900_B28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2013.01.034","article-title":"Xist RNA is a potent suppressor of hematologic cancer in mice","volume":"152","author":"Yildirim","year":"2013","journal-title":"Cell"},{"issue":"7346","key":"2019111705375262900_B29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature09999","article-title":"A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia","volume":"473","author":"Klinakis","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2019111705375262900_B30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.exphem.2011.12.004","article-title":"Mice heterozygous for CREB binding protein are hypersensitive to gamma-radiation and invariably develop myelodysplastic\/myeloproliferative neoplasm","volume":"40","author":"Zimmer","year":"2012","journal-title":"Exp Hematol"},{"issue":"9","key":"2019111705375262900_B31","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/blood-2010-02-267906","article-title":"Reduced NR4A gene dosage leads to mixed myelodysplastic\/myeloproliferative neoplasms in mice","volume":"117","author":"Ramirez-Herrick","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111705375262900_B32","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","article-title":"Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis","volume":"31","author":"Elliott","year":"2007","journal-title":"Leuk Res"},{"issue":"17","key":"2019111705375262900_B33","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111705375262900_B34","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2019111705375262900_B35","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111705375262900_B36","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111705375262900_B37","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"3","key":"2019111705375262900_B38","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111705375262900_B39","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic\u2013French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111705375262900_B40","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2019111705375262900_B41","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"2019111705375262900_B42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"Park","year":"2013","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019111705375262900_B43","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3324\/haematol.2013.084020","article-title":"Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups","volume":"98","author":"Onida","year":"2013","journal-title":"Haematologica"},{"issue":"21","key":"2019111705375262900_B44","doi-asserted-by":"crossref","first-page":"26622670","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111705375262900_B45","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bmt.2011.141","article-title":"Current status of allogeneic HST for chronic myelomonocytic leukemia","volume":"47","author":"Cheng","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"2019111705375262900_B46","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111705375262900_B47","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"issue":"14","key":"2019111705375262900_B48","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111705375262900_B49","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1172\/JCI78752","article-title":"Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia","volume":"125","author":"Meldi","year":"2015","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111705375262900_B50","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","article-title":"Refractory anemia with ring sideroblasts and marked thrombocytosis (RARS-T) cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations","volume":"100","author":"Jeromin","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"2019111705375262900_B51","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2010-01-263087","article-title":"Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis","volume":"116","author":"Huls","year":"2010","journal-title":"Blood"},{"key":"2019111705375262900_B52","first-page":"718480","article-title":"Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia","volume":"2013","author":"Taylor","year":"2013","journal-title":"Case Rep Hematol"},{"issue":"2","key":"2019111705375262900_B53","first-page":"105","article-title":"Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome","volume":"61","author":"Ziarkiewicz","year":"2010","journal-title":"Pol J Pathol"},{"issue":"1","key":"2019111705375262900_B54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000345851","article-title":"Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon alpha-2b","volume":"130","author":"Zhang","year":"2013","journal-title":"Acta Haematol"},{"issue":"9","key":"2019111705375262900_B55","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"2019111705375262900_B56","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/10428190310001593175","article-title":"Phase I\/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia","volume":"45","author":"Weihrauch","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2019111705375262900_B57","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"17","author":"Beran","year":"1999","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111705375262900_B58","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"issue":"7","key":"2019111705375262900_B59","first-page":"1164","article-title":"All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study","volume":"10","author":"Cambier","year":"1996","journal-title":"Leukemia"},{"issue":"16","key":"2019111705375262900_B60","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1002\/cncr.26741","article-title":"A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) or primary myelofibrosis (PMF)","volume":"118","author":"Bejanyan","year":"2012","journal-title":"Cancer"},{"issue":"25","key":"2019111705375262900_B61","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/349\/1250226\/bep00115000349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/349\/1250226\/bep00115000349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T10:38:17Z","timestamp":1573987097000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/349\/20664\/Surveying-the-landscape-of-MDSMPN-research-overlap"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.349","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}